The MultipleMS Consortium has been granted €15M by the EU Horizon 2020 to improve the treatment of multiple sclerosis using personalised medicine.
The EU Horizon 2020 has kicked off the year with a project to develop, validate, and exploit methods for the personalised treatment of multiple sclerosis (MS). The 21 institutions from 12 European countries and the US taking part in the MultipleMS Consortium, coordinated by the Karolinska Institutet in Stockholm, will receive €15M to study how genetic and non-genetic factors influence disease progression and response to therapy.
By using a multi omics approach that integrates genome, epigenome, proteome, metabolome and microbiome data, the project aims at stratifying the MS patient population to offer personalised treatments and optimise the outcome.
Jean-Pol Detiffe, CEO of OncoDNA, said during a personalised medicine panel at Labiotech Refresh: “biology is complex and a successful test cannot only rely on genes”. The combination of biomarkers from multiple origins using multi omics might be the key for a new generation of successful diagnostics and treatments in personalised medicine.
Source: Labiotech.eu © Labiotech UG (05/01/17)